middle.news
NeuroScientific Secures StemSmart Tech, Targets Crohn’s Disease Breakthrough
9:39am on Friday 27th of June, 2025 AEST
•
Healthcare
Read Story
NeuroScientific Secures StemSmart Tech, Targets Crohn’s Disease Breakthrough
9:39am on Friday 27th of June, 2025 AEST
Key Points
Acquisition of Isopogen WA grants full rights to patented StemSmart stem cell technology
Raised approximately $7.5 million through institutional placement
New board appointments – Robert McKenzie as Chair, Paul Fry as Non-Executive Director
Special Access Program launched for fistulising Crohn’s disease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE